Supernus reports Q2 EPS 40c vs. 36c last year

Reports Q2 revenue $165.5M, consensus $154.08M. “Our strong operating performance in the first half of the year was driven by continued strong sales growth of Qelbree and GOCOVRI, which combined accounted for 72% of total net sales in the second quarter of 2025,” said Jack Khattar, President and CEO of Supernus (SUPN). “Our focus for the second half of the year remains on the launch of ONAPGO, the successful integration of Sage Therapeutics, and the continued performance of our growth products.”